Biotech Values

[mcbio]

the MRK BACE program is indeed from Ligand. Phase 1 single dose showed the 58% reduction mentioned in LGND 10k, Phase 1 multidose showed 90% reduction (November 2011 MRK slides), and phase 2 to start 2012.

As is the case for numerous of their programs, Ligand knows nothing more than what MRK has put out publicly.

Just to follow up on this, why doesn't LGND disclose this particular project in its pipeline on its Web site (http://www.ligand.com/pipeline )? Also, if you click on the "Collaborations" part of LGND's Web site and click on Merck (http://www.ligand.com/merck ), it only discloses a CDK inhibitor for cancer in Phase 2. Curiously missing on the entire Web site is the BACE inhibitor. Are we sure that the MRK BACE inhibitor is from LGND?